Salivary Gland. Photon beam and particle radiotherapy: Present and future

Research output: Contribution to journalArticle

Abstract

Salivary gland cancers (SGCs) are rare diseases and their treatment depends upon histology, stage and site of origin. Radical surgery is the mainstay of treatment but radiotherapy (RT) plays a key role in both the postoperative and the inoperable setting, as well as in recurrent disease. In the absence of prospective randomized trials, a wide retrospective literature suggests postoperative RT (PORT) in patients with high risk pathological features.SGCs, and adenoid cystic carcinoma (ACC) in particular, are known to be radio-resistant tumors and should therefore respond well to particle beam therapy. Recently, excellent outcome has been reported with radical carbon ion RT (CIRT) in particular for ACC. Both modern photon- and hadron-based treatments are effective and are characterized by a favourable toxicity profile. But it is not clear whether one modality is superior to the other for disease control, due to the differences in patients' selection, techniques, fractionation schedules and outcome measurements among clinical experiences.In this paper, we review the role of photon and particle RT for malignant SGCs, discussing the difference between modalities in terms of biological and technical characteristics. RT dose and target volumes for different histologies (ACC versus non-ACC) have also been taken into consideration.

Original languageEnglish
JournalOral Oncology
DOIs
Publication statusAccepted/In press - Feb 10 2016

    Fingerprint

Keywords

  • Adenoid cystic carcinoma
  • Carbon ion therapy
  • Definitive radiotherapy
  • Intensity modulated radiation therapy
  • Malignant salivary gland cancers
  • Particle beam therapy
  • Postoperative radiotherapy
  • Proton therapy

ASJC Scopus subject areas

  • Oncology
  • Oral Surgery
  • Cancer Research

Cite this